Targeted Protein Degradation Market CAGR To Be Around 32% by 2035 | Roots Analysis

Over time, advancements in understanding cellular mechanisms and proteomics have spurred researchers to adopt an innovative approach known as targeted protein degradation. This approach aims to selectively break down specific proteins associated with diseases by harnessing cellular machinery utilizing small molecules.

Targeted protein degradation employs modalities responsible for protein destruction, offering advantages such as specificity, stability, and minimal off-target effects. Bolstered by these advantages and ongoing technological advancements, the targeted protein degradation market is expected to witness significant growth during the forecast period.

Market Segments

Based on the type of degrader, the market is segmented into SERDs, PROTACs and Molecular Glues

SERDs are likely to lead the market for targeted protein degradation, capturing the largest revenue share in 2024.

PROTACs are anticipated to show the highest growth rate during the forecast period of around 28% annually.

Based on the target indication, the market is segmented into Breast Cancer and Multiple Myeloma

Targeted protein degradation therapies intended for breast cancer led the market for targeted protein degradation, capturing the largest revenue share in 2024.

Targeted protein degradation therapies intended for breast cancer are anticipated to show the highest growth rate during the forecast period of around 30% annually.

Targeted Protein Degradation Market Regional Outlook

Based on the key geographical regions, the market can be segmented into four major regions, including North America, Europe, Asia-Pacific and rest of the world. North America is anticipated to capture the majority share of the targeted protein degradation market in 2024 and this trend is likely to remain unchanged during the forecast period. Further, the targeted protein degradation industry in Asia-Pacific is accounted to be the fastest-growing segment of the market. This is primarily due to the increasing number of biopharmaceutical startups and likely drug approvals in the region for treatment of various oncological indications.?

Key Report Takeaways

Currently, more than 285 targeted protein degradation therapies are either approved or being investigated in different stages of development

At present, around 85 innovative targeted protein degradation technologies are available for developing stable and efficacious degraders

Around 250 clinical trials are currently underway to investigate targeted protein degradation therapies intended for treatment of various diseases, across different geographies

Grants worth over USD 165 million have been awarded since 2019; additionally, ~80% of these grants were awarded for a support period of 1-4 years

More than 985 patents have been filed / granted were focused on targeted protein degraders and related technologies, by industry and non-industry players, to protect the intellectual property generated within this field

In the last five years, several articles focused on targeted protein degraders and related technologies have been published in various high-impact journals, especially in the Asia-Pacific region

Owing to the financial prosperity and the cultural norms present in the region, the US has emerged as a hub of the established players and the new entrants in this industry

Post-2019, a considerable increase in partnership activity has been witnessed in this domain; 25% of the deals were focused on research and development of novel candidates, signed primarily by the players based in the US

Several investors have realized the opportunity within the domain of targeted protein degradation and invested around USD 13.5 billion across various funding rounds in the past six years

Owing to the protein degraders ability to degrade the undruggable targets selectively, the targeted protein degradation therapies market is anticipated to witness an annualized growth of 32%, over the next decade

The targeted protein degradation technologies market is expected to grow at an annualized rate of 7.5% between 2024 and 2035; the projected opportunity is anticipated to be well distributed across different payment models

Key Players

Examples of key companies engaged in targeted protein degradation market (which have also been profiled in this market report; the complete list of companies is available in the full report) include (in alphabetic order) Arvinas, AstraZeneca, BeiGene, Bristol-Myers Squibb, C4 Therapeutics, Eisai Therapeutics, InnoCare Pharma, Kangpu Biopharmaceuticals, Kintor Pharmaceutical, Loxo Oncology, Medivir, Monte Rosa Therapeutics, Olema Oncology, Radius Health, Ranok Therapeutics, Roche, Sanofi and Zentalis Pharmaceuticals.

About Roots Analysis

Roots Analysis is a global leader in the market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

Contact Details

Gaurav Chaudhary

Email: sales@rootsanalysis.com